Delivery Order SPE2DR25D1100-SPE2DR26FCU6F
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $2,669.03 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens. This competitive award, issued on October 30, 2025, with an ultimate completion date of October 31, 2025, represents a firm fixed price transaction for pharmaceutical delivery to support federal medical supply needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a $17,804.99 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on December 12, 2025, with an ultimate completion date of December 15, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award under the company's broader pharmaceutical supply relationship with the federal government. The award was placed to AmerisourceBergen's Corporate Office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $15,446.43 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on November 26, 2025, with an ultimate completion date of November 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a $13,067.60 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens under a firm fixed price contract. The order is scheduled for completion by August 8, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a relatively small-value transaction...
- The Defense Logistics Agency awarded a delivery order valued at $4,483.14 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on a firm fixed-price basis. The contract, which was competitively awarded without set-aside designation, was executed on December 10, 2025, with an ultimate completion date of December 11, 2025. Performance will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,766.15 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 14, 2025, with completion expected by July 15, 2025. This competitively awarded, firm fixed-price delivery order supports federal medical procurement needs and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's proven...
- The Defense Logistics Agency awarded a delivery order valued at $10,128.30 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens. This is a firm fixed-price delivery order with a completion date of August 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with...
- The Defense Logistics Agency awarded a $17,564.19 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within the company's...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCU6FDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,247.59 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 ml pens on December 12, 2025, with final completion scheduled for December 15, 2025. This firm fixed price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The order represents a routine pharmaceutical procurement supporting federal healthcare operations. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medications and medical commodities to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The company maintains an extensive portfolio of federal contract awards demonstrating its capability to fulfill competitive procurement requirements across diverse therapeutic domains and transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 12/11/25 |